TY - JOUR
T1 - Harnessing omics approaches on advanced preclinical models to discovery novel therapeutic targets for the treatment of metastatic colorectal cancer
AU - Porru, Manuela
AU - Zizza, Pasquale
AU - Panera, Nadia
AU - Alisi, Anna
AU - Biroccio, Annamaria
AU - Leonetti, Carlo
N1 - Funding Information:
Funding: This research and the APC were funded by the Italian Association for Cancer Research (AIRC), IG grant 18637 (CL) and by an intramural grant-in-aid funded by the Italian Ministry of Health (MP and PZ).
Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/7
Y1 - 2020/7
N2 - Metastatic colorectal cancer (mCRC) remains challenging because of the emergence of resistance mechanisms to anti-epidermal growth factor receptor (EGFR) therapeutics, so more effective strategies to improve the patients’ outcome are needed. During the last decade, the application of a multi-omics approach has contributed to a deeper understanding of the complex molecular landscape of human CRC, identifying a plethora of drug targets for precision medicine. Target validation relies on the use of experimental models that would retain the molecular and clinical features of human colorectal cancer, thus mirroring the clinical characteristics of patients. In particular, organoids and patient-derived-xenografts (PDXs), as well as genetically engineered mouse models (GEMMs) and patient-derived orthotopic xenografts (PDOXs), should be considered for translational purposes. Overall, omics and advanced mouse models of cancer represent a portfolio of sophisticated biological tools that, if optimized for use in concert with accurate data analysis, could accelerate the anticancer discovery process and provide new weapons against cancer. In this review, we highlight success reached following the integration of omics and experimental models; moreover, results produced by our group in the field of mCRC are also presented.
AB - Metastatic colorectal cancer (mCRC) remains challenging because of the emergence of resistance mechanisms to anti-epidermal growth factor receptor (EGFR) therapeutics, so more effective strategies to improve the patients’ outcome are needed. During the last decade, the application of a multi-omics approach has contributed to a deeper understanding of the complex molecular landscape of human CRC, identifying a plethora of drug targets for precision medicine. Target validation relies on the use of experimental models that would retain the molecular and clinical features of human colorectal cancer, thus mirroring the clinical characteristics of patients. In particular, organoids and patient-derived-xenografts (PDXs), as well as genetically engineered mouse models (GEMMs) and patient-derived orthotopic xenografts (PDOXs), should be considered for translational purposes. Overall, omics and advanced mouse models of cancer represent a portfolio of sophisticated biological tools that, if optimized for use in concert with accurate data analysis, could accelerate the anticancer discovery process and provide new weapons against cancer. In this review, we highlight success reached following the integration of omics and experimental models; moreover, results produced by our group in the field of mCRC are also presented.
KW - Anti-EGF
KW - Colon cancer
KW - GEMM
KW - New therapies
KW - Omics technologies
KW - Organoids
KW - Orthotopic tumors
KW - PDXs
UR - http://www.scopus.com/inward/record.url?scp=85087761351&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087761351&partnerID=8YFLogxK
U2 - 10.3390/cancers12071830
DO - 10.3390/cancers12071830
M3 - Review article
AN - SCOPUS:85087761351
VL - 12
SP - 1
EP - 17
JO - Cancers
JF - Cancers
SN - 2072-6694
IS - 7
M1 - 1830
ER -